$2.13
-0.03-1.24%
At close: -
$2.62
0.4922.82%
After Hours: Oct 18, 7:54 AM EDT
15 minutes delayed
Comments
Loading...
Akari Therapeutics (AKTX) Forecast
NewsEarningsAkari Therapeutics (AKTX) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestAkari Therapeutics (NASDAQ:AKTX) Stock Quotes, Forecast and News Summary
Akari Therapeutics Stock (NASDAQ: AKTX) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Akari Therapeutics (AKTX) stock?
You can purchase shares of Akari Therapeutics (NASDAQ:AKTX) through any online brokerage.
Who are Akari Therapeutics (AKTX) competitors?
Other companies in Akari Therapeutics’s space includes: Estrella Immunopharma (NASDAQ:ESLA), T2 Biosystems (NASDAQ:TTOO), Lumos Pharma (NASDAQ:LUMO), Aligos Therapeutics (NASDAQ:ALGS) and Bolt Biotherapeutics (NASDAQ:BOLT).
What is the forecast, or price target, for Akari Therapeutics (AKTX) stock?
Akari Therapeutics has a consensus price target of $2.75.
What is the current price for Akari Therapeutics (AKTX)?
The stock price for Akari Therapeutics (NASDAQ: AKTX) is $2.1332 last updated October 22, 2024 at 1:40 PM EDT.
Does Akari Therapeutics (AKTX) pay a dividend?
There are no upcoming dividends for Akari Therapeutics.
When is Akari Therapeutics (NASDAQ:AKTX) reporting earnings?
Akari Therapeutics’s Q3 earnings are confirmed for Tuesday, November 19, 2024.
Is Akari Therapeutics (AKTX) going to split?
There is no upcoming split for Akari Therapeutics.
What sector and industry does Akari Therapeutics (AKTX) operate in?
Akari Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.